ReviewAmino acids2011
Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors.
Review in Amino acids, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 78 citations in OpenAlex.
- Clinical application of targeted α-emitter therapy in gastroenteropancreatic neuroendocrine neoplasms.Journal of gastroenterology · 2025Review
- Radiotheranostic landscape: A review of clinical and preclinical development.European journal of nuclear medicine and molecular imaging · 2025Review
- Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication.European journal of nuclear medicine and molecular imaging · 2024Review
- Effect ofPharmaceutics · 2023Article
- Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Automated Synthesis ofMolecules (Basel, Switzerland) · 2022Article
- Review
- Advances in Development of Radiometal Labeled Amino Acid-Based Compounds for Cancer Imaging and Diagnostics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Preliminary Study of a 1,5-Benzodiazepine-Derivative Labelled with Indium-111 for CCK-2 Receptor Targeting.Molecules (Basel, Switzerland) · 2021Article
- Stabilization Strategies for Linear Minigastrin Analogues: Further ImprovementsJournal of medicinal chemistry · 2020Article
- Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy.Journal of clinical medicine · 2020Review
- Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.Molecules (Basel, Switzerland) · 2020Article
- [Molecular pharmaceutics · 2020Article
- Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions.Current medicinal chemistry · 2020Review
- The functions and applications of A7R in anti-angiogenic therapy, imaging and drug delivery systems.Asian journal of pharmaceutical sciences · 2019Review
- Peptide Receptor Radiotherapy: Current Approaches and Future Directions.Current treatment options in oncology · 2019Review
- DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m.Pharmaceuticals (Basel, Switzerland) · 2019Article
- Less Exploited GPCRs in Precision Medicine: Targets for Molecular Imaging and Theranostics.Molecules (Basel, Switzerland) · 2018Review
- Exploiting the Concept of Multivalency withContrast media & molecular imaging · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholecystokinin (CCK) receptors are overexpressed in numerous human cancers, like medullary thyroid carcinomas, small cell lung cancers and stromal ovarian cancers. The specific receptor-binding property of the endogenous ligands for these receptors can be exploited by labeling peptides with a radionuclide and using these as carriers to guide the radioactivity to the tissues that express the receptors. In this way, tumors can be visualized using positron emission tomography and single photon emission computed tomography imaging. A variety of radiolabeled CCK/gastrin-related peptides has been synthesized and characterized for imaging. All peptides have the C-terminal CCK receptor-binding tetrapeptide sequence Trp-Met-Asp-Phe-NH(2) in common or derivatives thereof. This review focuses on the development and application of radiolabeled CCK/gastrin peptides for radionuclide imaging and radionuclide therapy of tumors expressing CCK receptors. We discuss both preclinical studies as well as clinical studies with CCK and gastrin peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.